A new study suggests that more women are being prescribed beta-3 agonists over anticholinergics for the treatment of overactive bladder (OAB), suggesting that more clinicians may be choosing this ...

Before you start treatment with Myrbetriq, tell your doctor and pharmacist which prescription, over-the-counter, and other medications you take. By sharing this information with them, you may help ...

Bladder leaks can be disruptive—and they’re very common. Up to 30 percent of older adults experience incontinence. The problem is more prevalent in women, but the percentage of men with an overactive ...

Researchers report that oxybutynin outperformed placebo in lowering daily hot flash frequency and intensity among men on hormone therapy for prostate cancer. The drug also enhanced sleep, social ...

If frequent bathroom trips disrupt your life, you are not alone. Women's health expert Kirtly Jones, MD, talks to urogynecologist Whitney Hendrickson, MD, about the complexities of overactive bladder ...

After successful Phase 3 trials, Indevus Pharmaceuticals Inc. has received a $10 million milestone payment from its partner in the development of overactive-bladder drugs Sanctura and Sactura XR, ...

Consumer Reports has no financial relationship with any advertisers on this site. Bladder leaks can be disruptive — and they’re very common. Up to 30 percent of older adults experience incontinence.

Do you often feel a sudden, intense urge to urinate that disrupts your daily life? If so, you may be experiencing one of the most common overactive bladder symptoms. Understanding the signs to look ...

Lupin resolves patent dispute with Astellas, agreeing to pay $90 million to continue selling Mirabegron for overactive ...

Zydus Lifesciences has reached a settlement agreement with Astellas in a patent dispute involving overactive bladder therapy Myrbetriq, which will allow its generic to remain on sale in the US.